Mutation analysis of TP53 in colorectal cancer, Peshawar, Khyber Pakhtunkhwa, Pakistan.

Ihsan Ali 1, Aamna Fayyaz 2, Zahid Anwar 3, Irfan Saif 4, Ikram Khan 4, Muhammad Jahangir 5, Mian Adnan Kakakhel 4 *
More Detail
1 College of Life Science, Northwest University, Xi’an, Shaanxi province, China
2 Department of Zoology, Kohat University of Science and Technology, Kohat, Khyber Pakhtunkhwa, Pakistan
3 Animal Sciences Institute, Faculty of Animal Genomics and Biotechnology, PARC Institute of Advanced Studies in Agriculture, National Agricultural Research Center, Islamabad, Pakistan
4 MOE Key Laboratory of Cell Activities and Stress Adaptations, School of Life Sciences, Lanzhou University, Lanzhou, China
5 National Clinical Research Center for Mental Disorders, Xiangya School of Medicine, Central South University, Changsha, Hunan, China
* Corresponding Author
J CLIN MED KAZ, Volume 18, Issue 2, pp. 25-30.
Download Full Text (PDF)


Aim: Colorectal cancer is a kind of solid tumor and third most common of cancer which leads to death. It is a heterogeneous disease characterized by genetic and epigenetic aberrations. The present study was aimed to reveal the mutation at TP53 in Peshawar Pakistan.
Material and methods: For this purpose, a total of 50 blood samples in EDTA tubes was collected from Peshawar with complete information of patients using questionnaire. The polymerase chain reaction was performed.
Results: The results of the present study have revealed that the ratio of colorectal cancer in males is higher 62% than females (38%). Histopathological results have indicated that moderately differentiated adenocarcinoma is 25 (50%) followed by poorly differentiated adenocarcinoma 15 (30%), Well-differentiated adenocarcinoma 8 (16%), and Metastatic adenocarcinoma 2 (4%) in 50 colorectal cancer patients. The nucleotide sequence of the human TP53 gene of colorectal cancer patients was aligned with the human wild-type TP53 database sequence with NC_191170 (NCBI) using CLUSTALW. After BLASTING, the mutation was found in exon 5 and exon 7 of TP53, while no mutation was found in exon 8 of TP53. That patient in which point mutation was found in exon 5 and 7 respectively showed less survival as compared to that of colorectal cancer patients having no point mutation in the TP53 gene.
Conclusion: The present study concluded that point mutations were found in exons 5&7 of the TP53 gene and patients having TP53 gene mutations shown less survival rate compared to colorectal cancer patients having no mutations.


Ali I, Fayyaz A, Anwar Z, Saif I, Khan I, Jahangir M, et al. Mutation analysis of TP53 in colorectal cancer, Peshawar, Khyber Pakhtunkhwa, Pakistan.. J CLIN MED KAZ. 2021;18(2):25-30.


  • Anwar, N., Badar, F., Yusuf, M.A., 2008. Profile of patients with colorectal cancer at a tertiary care cancer hospital in Pakistan. Ann. N. Y. Acad. Sci. 1138, 199-203.
  • Bhurgri, Y., Khan, T., Kayani, N., Ahmad, R., Usman, A., Bhurgri, A., Bashir, I., Hasan, S., Zaidi, S.M.H., 2011. Incidence and current trends of colorectal malignancies in an unscreened, low risk population. Asian Pacific J. Cancer Prev. 12, 703-708.
  • Brigger, I., Dubernet, C., Couvreur, P., 2012. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 64, 24-36.
  • Duffy, M.J., Synnott, N.C., Crown, J., 2017. Mutant p53 as a target for cancer treatment. Eur. J. Cancer 83, 258-265.
  • Frebourg, T., Friend, S.H., 1992. Cancer risks from germline p53 mutations. J. Clin. Invest. 90, 1637-1641.
  • Gao, Z.-G., Yang, Y., Han, X.-F., Wang, Y.-L., Wang, Z.-J., 2020. ALDH3B2 Polymorphism Is Associated with Colorectal Cancer Susceptibility. J. Oncol. 2020, 5179635.
  • George, B., Datar, R.H., Wu, L., Cai, J., Patten, N., Beil, S.J., Groshen, S., Stein, J., Skinner, D., Jones, P.A., 2007. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J. Clin. Oncol. 25, 5352-5358.
  • Ghorbani, F., Kokhaei, P., Ghorbani, M., Eslami, M., 2020. Application of different nanoparticles in the diagnosis of colorectal cancer. Gene Reports 21, 100896.
  • Haggar, F.A., Boushey, R.P., 2009. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin. Colon Rectal Surg. 22, 191.
  • Hasan, F., Shah, S.M.M., Munaf, M., Khan, M.R., Marsia, S., Haaris, S.M., Shaikh, M.H., Rahim, I.A., Anwar, M.S., Qureshi, K.S., 2017. Barriers to colorectal cancer screening in Pakistan. Cureus 9.
  • Iacopetta, B., Russo, A., Bazan, V., Dardanoni, G., Gebbia, N., Soussi, T., Kerr, D., Elsaleh, H., Soong, R., Kandioler, D., 2006. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann. Oncol. 17, 842-847.
  • Kakakhel, M.A., Wu, F., Gu, J.-D., Feng, H., Shah, K., Wang, W., 2019. Controlling biodeterioration of cultural heritage objects with biocides: A review. Int. Biodeterior. Biodegradation 143, 104721.
  • Moghimi-Dehkordi, B., Safaee, A., 2012. An overview of colorectal cancer survival rates and prognosis in Asia. World J. Gastrointest. Oncol. 4, 71.
  • Naccarati, A., Polakova, V., Pardini, B., Vodickova, L., Hemminki, K., Kumar, R., Vodicka, P., 2012. Mutations and polymorphisms in TP53 gene-an overview on the role in colorectal cancer. Mutagenesis 27, 211-218.
  • Nejad, A.L., Yaghoobi, M.M., 2012. Mutation analysis of TP53 tumor suppressor gene in colorectal cancer in patients from Iran (Kerman Province). Iran. J. Basic Med. Sci. 15, 683.
  • Olivier, M., Hollstein, M., Hainaut, P., 2010. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2, a001008.
  • Osumi, H., Shinozaki, E., Yamaguchi, K., Zembutsu, H., 2019. Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer. Sci. Rep. 9, 1-9.
  • Qadir, M., Ghalia, B.A., 2018. Awareness survey about colorectal cancer in students of M. Phil Biotechnology at Bahauddin Zakariya University, Multan, Pakistan. Nov Appro Can Study 1.
  • Rehman, G., Gul, N., Khan, G.N., Zaman, K., Anwar, Z., Kakakhel, M.A., 2020. Ethanolic extract of Allacanthos crab inhibits cancer cell proliferation, posses anti-inflammatory and antioxidant potentials. Gene Reports 21.
  • Roth, J.A., 1999. p53 prognostication: Paradigm or paradox? Clin. Cancer Res. 5, 3345.
  • Ryan, K.M., Phillips, A.C., Vousden, K.H., 2001. Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol. 13, 332-337.
  • Sharma, A., Alatise, O.I., Adisa, A.O., Arowolo, O.A., Olasehinde, O., Famurewa, O.C., Omisore, A.D., Komolafe, A.O., Olaofe, O., Katung, A.I., 2020. Treatment of colorectal cancer in Sub‐Saharan Africa: Results from a prospective Nigerian hospital registry. J. Surg. Oncol. 121, 342-349.
  • Shen, J., Vakifahmetoglu, H., Stridh, H., Zhivotovsky, B., Wiman, K.G., 2016. PRIMA-1Met induces mitochondrial apoptosis through activation of caspase-2. Oncogene 35, 6446.
  • Siegel, R.L., Miller, K.D., 2015. Jemal A: Cancer statistics, 2015. CA Cancer j Clin 65, 5-29.
  • Tominaga, T., Iwahashi, M., Takifuji, K., Hotta, T., Yokoyama, S., Matsuda, K., Higashiguchi, T., Oku, Y., Nasu, T., Yamaue, H., 2010. Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5‐fluorouracil in colorectal cancer. Int. J. cancer 126, 1691-1701.
  • Warwick, P.D., 2007. Overview of the geography, geology and structure of the Potwar regional framework assessment project study area, north-ern Pakistan. Reg. Stud. Potwar Plateau Area, North. Pakistan. US Geol. Surv. Bull 2078.
  • Yu, J., Wu, W.K.K., Li, X., He, J., Li, X.-X., Ng, S.S.M., Yu, C., Gao, Z., Yang, J., Li, M., 2015. Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. Gut 64, 636-645.
  • Zhang, X., Wang, W., Wang, Y., Jia, D., Zhu, L., 2018. Human papillomavirus infection and colorectal cancer in the Chinese population: a meta‐analysis. Color. Dis. 20, 961-969.